187 related articles for article (PubMed ID: 17470431)
1. TIMP-3 inhibition of ADAMTS-4 (Aggrecanase-1) is modulated by interactions between aggrecan and the C-terminal domain of ADAMTS-4.
Wayne GJ; Deng SJ; Amour A; Borman S; Matico R; Carter HL; Murphy G
J Biol Chem; 2007 Jul; 282(29):20991-8. PubMed ID: 17470431
[TBL] [Abstract][Full Text] [Related]
2. Autocatalytic cleavage of ADAMTS-4 (Aggrecanase-1) reveals multiple glycosaminoglycan-binding sites.
Flannery CR; Zeng W; Corcoran C; Collins-Racie LA; Chockalingam PS; Hebert T; Mackie SA; McDonagh T; Crawford TK; Tomkinson KN; LaVallie ER; Morris EA
J Biol Chem; 2002 Nov; 277(45):42775-80. PubMed ID: 12202483
[TBL] [Abstract][Full Text] [Related]
3. ADAMTS-5 deficiency does not block aggrecanolysis at preferred cleavage sites in the chondroitin sulfate-rich region of aggrecan.
East CJ; Stanton H; Golub SB; Rogerson FM; Fosang AJ
J Biol Chem; 2007 Mar; 282(12):8632-40. PubMed ID: 17255106
[TBL] [Abstract][Full Text] [Related]
4. Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases.
Troeberg L; Fushimi K; Khokha R; Emonard H; Ghosh P; Nagase H
FASEB J; 2008 Oct; 22(10):3515-24. PubMed ID: 18632849
[TBL] [Abstract][Full Text] [Related]
5. The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage.
Tortorella M; Pratta M; Liu RQ; Abbaszade I; Ross H; Burn T; Arner E
J Biol Chem; 2000 Aug; 275(33):25791-7. PubMed ID: 10827174
[TBL] [Abstract][Full Text] [Related]
6. Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing.
Kashiwagi M; Enghild JJ; Gendron C; Hughes C; Caterson B; Itoh Y; Nagase H
J Biol Chem; 2004 Mar; 279(11):10109-19. PubMed ID: 14662755
[TBL] [Abstract][Full Text] [Related]
7. Aggrecanase and aggrecan degradation in osteoarthritis: a review.
Huang K; Wu LD
J Int Med Res; 2008; 36(6):1149-60. PubMed ID: 19094423
[TBL] [Abstract][Full Text] [Related]
8. Effects of covalently attached chondroitin sulfate on aggrecan cleavage by ADAMTS-4 and MMP-13.
Miwa HE; Gerken TA; Hering TM
Matrix Biol; 2006 Oct; 25(8):534-45. PubMed ID: 16945513
[TBL] [Abstract][Full Text] [Related]
9. Reactive-site mutants of N-TIMP-3 that selectively inhibit ADAMTS-4 and ADAMTS-5: biological and structural implications.
Lim NH; Kashiwagi M; Visse R; Jones J; Enghild JJ; Brew K; Nagase H
Biochem J; 2010 Oct; 431(1):113-22. PubMed ID: 20645923
[TBL] [Abstract][Full Text] [Related]
10. Alpha2-macroglobulin is a novel substrate for ADAMTS-4 and ADAMTS-5 and represents an endogenous inhibitor of these enzymes.
Tortorella MD; Arner EC; Hills R; Easton A; Korte-Sarfaty J; Fok K; Wittwer AJ; Liu RQ; Malfait AM
J Biol Chem; 2004 Apr; 279(17):17554-61. PubMed ID: 14715656
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor 2 inhibits induction of aggrecanase activity in human articular cartilage.
Sawaji Y; Hynes J; Vincent T; Saklatvala J
Arthritis Rheum; 2008 Nov; 58(11):3498-509. PubMed ID: 18975307
[TBL] [Abstract][Full Text] [Related]
12. The nutraceutical flavonoid luteolin inhibits ADAMTS-4 and ADAMTS-5 aggrecanase activities.
Moncada-Pazos A; Obaya AJ; Viloria CG; López-Otín C; Cal S
J Mol Med (Berl); 2011 Jun; 89(6):611-9. PubMed ID: 21365186
[TBL] [Abstract][Full Text] [Related]
13. Release of hyaluronan and hyaladherins (aggrecan G1 domain and link proteins) from articular cartilage exposed to ADAMTS-4 (aggrecanase 1) or ADAMTS-5 (aggrecanase 2).
Chockalingam PS; Zeng W; Morris EA; Flannery CR
Arthritis Rheum; 2004 Sep; 50(9):2839-48. PubMed ID: 15457452
[TBL] [Abstract][Full Text] [Related]
14. Screening of potential a disintegrin and metalloproteinase with thrombospondin motifs-4 inhibitors using a collagen model fluorescence resonance energy transfer substrate.
Lauer-Fields JL; Spicer TP; Chase PS; Cudic M; Burstein GD; Nagase H; Hodder P; Fields GB
Anal Biochem; 2008 Feb; 373(1):43-51. PubMed ID: 17949675
[TBL] [Abstract][Full Text] [Related]
15. The C-terminal domains of ADAMTS-4 and ADAMTS-5 promote association with N-TIMP-3.
Troeberg L; Fushimi K; Scilabra SD; Nakamura H; Dive V; Thøgersen IB; Enghild JJ; Nagase H
Matrix Biol; 2009 Oct; 28(8):463-9. PubMed ID: 19643179
[TBL] [Abstract][Full Text] [Related]
16. Substrate-dependent inhibition kinetics of an active site-directed inhibitor of ADAMTS-4 (Aggrecanase 1).
Wittwer AJ; Hills RL; Keith RH; Munie GE; Arner EC; Anglin CP; Malfait AM; Tortorella MD
Biochemistry; 2007 May; 46(21):6393-401. PubMed ID: 17487981
[TBL] [Abstract][Full Text] [Related]
17. Glycosaminoglycan-binding properties and aggrecanase activities of truncated ADAMTSs: comparative analyses with ADAMTS-5, -9, -16 and -18.
Zeng W; Corcoran C; Collins-Racie LA; Lavallie ER; Morris EA; Flannery CR
Biochim Biophys Acta; 2006 Mar; 1760(3):517-24. PubMed ID: 16507336
[TBL] [Abstract][Full Text] [Related]
18. ADAMTS-4_v1 is a splice variant of ADAMTS-4 that is expressed as a protein in human synovium and cleaves aggrecan at the interglobular domain.
Wainwright SD; Bondeson J; Caterson B; Hughes CE
Arthritis Rheum; 2013 Nov; 65(11):2866-75. PubMed ID: 23897278
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage.
Malfait AM; Liu RQ; Ijiri K; Komiya S; Tortorella MD
J Biol Chem; 2002 Jun; 277(25):22201-8. PubMed ID: 11956193
[TBL] [Abstract][Full Text] [Related]
20. Low molecular weight isoforms of the aggrecanases are responsible for the cytokine-induced proteolysis of aggrecan in a porcine chondrocyte culture system.
Powell AJ; Little CB; Hughes CE
Arthritis Rheum; 2007 Sep; 56(9):3010-9. PubMed ID: 17763444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
